JMP Securities Downgrades Intra-Cellular Therapies (ITCI) to Market Perform
Get Alerts ITCI Hot Sheet
Price: $69.20 -0.75%
Rating Summary:
17 Buy, 3 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Rating Summary:
17 Buy, 3 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
JMP Securities downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Market Outperform to Market Perform and removed its price target (prior $55.00).
For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.
Shares of Intra-Cellular Therapies closed at $42.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Monness, Crespi, Hardt Downgrades Palantir Technologies Inc. (PLTR) to Sell on 'egregiously rich valuation... darkest days of this economic downturn are ahead of us'
- Compass Point Downgrades PebbleBrook Hotel Trust (PEB) to Neutral, 'could be several years before the company benefits fully from the significant investment over past years'
- Raymond James Downgrades Extra Space Storage (EXR) to Outperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
The Children's Investment Fund (TCI), JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!